Musella et al. identify an IFN-I → LSD2/KDM1B axis as a potent driver of cancer cell reprogramming, advocating for KDM1B targeting as a promising complement to immunogenic drugs to suppress CSC expansion and enhance the long-term efficacy of therapy. This evidence concerns the gene KDM1B and cancer.